Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

COVID-19 Clinical Trial

— ROCOVI  

Official title:

Multicentre Non-interventional Retrospective Cohort Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05196477
• Other study ID #: CL04041090
• Status: Completed
• Start date: July 14, 2021
• Est. completion date: August 29, 2022

Study information

• Verified date: January 2023
• Source: R-Pharm
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study purpose was to assess the outcomes of therapy with olokizumab within complex therapy of Coronavirus disease 2019 (COVID-19) in hospitalised patients in real clinical practice setting. The study investigated patients' characteristics, disease progression, and efficacy and safety of olokizumab therapy.

Description:

This was a multicentre retrospective cohort study of patients admitted to hospitals in various Russian Federation cities with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid (RNA) laboratory test for the treatment of severe acute respiratory syndrome. The study used information from primary medical documentation of COVID-19 patients who had underwent diagnostic and therapeutic procedures in accordance with the hospital clinical practice. Clinical and laboratory data was collected and analysed to assess olokizumab safety, investigate other treatments, course and outcomes of the disease. No additional tests or medical procedures were made as part of this study. If any data collected under the protocol was not available or not collected, they deemed lacking. Based on the results of preliminary assessment of the number of records from the patients meeting inclusion / exclusion criteria in the clinical sites planning to participate in the project it was planned to include no more than 3000 patients in the study, of which about 1500 would be in the main group (received olokizumab therapy), and 1500 would be in the comparison group. It was planned to conduct an analysis in the general population (including taking into account its balancing using statistical methods, in case of significant differences in the initial characteristics of patients in groups), as well as in a subpopulation selected from pairs formed taking into account the comparability of patients by individual characteristics. In total, it was planned to form at least 200 pairs (or more, if the included population is highly comparable). Participation of several clinics in Russian Federation cities (not more than 10 cites) was expected to assure sufficient population for the study. Data collection period for each hospitalised patient was equivalent to in-hospital period for the treatment of SARS-CoV-2 infection. Data collection by patients was made during hospital stay, including the day of discharge (treatment outcome or lethal outcome). The primary study variables were defined during 21-day observation period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3087
• Est. completion date: August 29, 2022
• Est. primary completion date: August 29, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of SARS-CoV-2 (using virus ribonucleic acid polymerase chain reaction (RNA PCR) test).
• Hospital admission for COVID-19 therapy.
• Infiltrative lung changes based on imaging findings (chest X-ray, chest computed tomography (CT)).
• Indications for Preemptive anti-inflammatory therapy (PAT), including two or more

signs below:

• reduced oxygen saturation of the blood SpO2 = 97 %
• C-reactive protein (CRP) > 15 mg/L
• body temperature > 37.5 °C for at least 3 days
• white blood cell count < 4.0 x 10^9/L
• absolute lymphocyte count < 2.0 x 10^9/L.
• Olokizumab therapy - for the test group.
• Source medical documents contain the information required for the study (lacking or incomplete data on some serum chemistry values are allowed: D-dimer, ferritin, IL-6, procalcitonin).

Exclusion Criteria:

• Inadequate information on patient's characteristics and therapy.
• Lack of documented confirmation of SARS-CoV-2 infection.
• Initiation of mechanical ventilation (MV) from the first day of admission in the control group or before olokizumab administration in the test group.
• Administration of systemic corticosteroids, IL-6, other immunosuppressants or immunoglobulins before hospital admission.
• Lack of indications to PAT
• Administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors - for comparator group.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Olokizumab
The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
• Standard therapy
Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.

Locations

Country	Name	City	State
Russian Federation	State Budgetary Healthcare Institution "Regional Hospital ? 3"	Chelyabinsk
Russian Federation	Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" under the Ministry of Health of the Russian Federation	Kazan	Tatarstan
Russian Federation	State Budgetary Healthcare Institution "City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department"	Moscow
Russian Federation	St. Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District"	Saint Petersburg
Russian Federation	State Budgetary Institution of Healthcare of Tver region "Regional clinical hospital"	Tver
Russian Federation	Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University of the Ministry for Healthcare of the Russian Federation	Ufa	The Republic Of Bashkortostan

Sponsors (4)

Lead Sponsor	Collaborator
R-Pharm	Almedis LLC, Data Management 365, ScienceFiles LLC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of patients who died during hospital admission due to any reason	The percentage of patients who died during hospital admission due to any reason in each therapy group	up to 21 days
Secondary	The percentage of patients who required mechanical ventilation or transfer to intensive care unit (ICU), or who died during hospital admission due to COVID-19	The percentage of patients who required mechanical ventilation or transfer to ICU, or who died after olokizumab therapy during hospital admission due to COVID-19.	up to day 21
Secondary	The percentage of patients who required transfer to ICU	The percentage of patients who required transfer to ICU in each therapy group	up to day 21
Secondary	The percentage of patients who required transfer to a new type of oxygen support and to an invasive mechanical ventilation (MV)	The transfer to a new type of oxygen support means the transfer to a more severe type of oxygen support (the appointment of low-current oxygen to patients who were initially without oxygen support; transfer from low-flow oxygen therapy to high-flow, non-invasive or invasive ventilation; from high-flow oxygen therapy to non-invasive or invasive ventilation; from non-invasive to invasive ventilation).	up to day 21
Secondary	Overall hospitalisation period	Overall hospitalisation period duration in each therapy group (in days)	from admission to discharge from hospital, up to 21 days